NTRK1/3 fusions were detected in only 0.7% of cases (12 ATC cases among 83 total NTRK fusion-positive tumours), highlighting a rare but clinically significant subgroup that may benefit from TRK inhibitors. The gene discussed is NTRK1; the disease is neoplasm.